MGC Pharmaceuticals Ltd Gains Green Light for Czech Republic Medical Cannabis Deal

Error message

The MailChimp PHP library is missing the required GuzzleHttp library. Please check the installation notes in README.txt.

Warning message

The subscription service is currently unavailable. Please try again later.

MGC Pharmaceuticals (ASX: MXC) has relisted on the Australian Securities Exchange and will move ahead with a $5 million planned capital raising after the ASX confirmed that MGC’s acquisition of a European medical cannabis company does not constitute a change of nature or scale under Chapter 11 listing rules.

The funds will be used to expand MGC’s European operations and to acquire Panax Pharma s.r.o., a Czech-based company holding a medical cannabis breeding license with access to growing space in the Vukoz Research Institute of the Czech Ministry of the Environment.

Under the agreement, MGC Pharma will be issued 25% equity in Panax upfront, and a further 55% for funding the next year’s operational costs, up to a maximum of €700,000 to acquire total 80% equity of Panax.

MGC will also have an option to acquire the final 20% equity in Panax by issuing €800,000 worth of MGC...

e-mail icon Facebook icon Twitter icon LinkedIn icon Reddit icon
Rate this article: 

This marijuana news is brought to you by 420 Intel. For the latest breaking cannabis industry news, subscribe to the 420 Intel newsletter. If you'd like to promote your product or service in this area after every article, contact us.